北米間質性膀胱炎市場、重症度別（軽度から中等度、中等度から重度）、治療タイプ別（薬物療法、膀胱点滴、ボツリヌス毒素A、神経刺激療法手術）、投与経路別（経口、非経口、膀胱内、局所、その他）、購入方法別（市販薬、処方薬）、患者タイプ別（小児および成人）、エンドユーザー別（病院、診療所、在宅医療、その他）、流通チャネル別（直接入札、小売販売、その他） - 2029年までの業界動向および予測。
北米間質性膀胱炎市場の分析と規模
間質性膀胱炎 (IC) と呼ばれる膀胱痛の症状は、原因不明の膀胱と骨盤底の持続的な痛みを引き起こします。これは女性泌尿器持続性骨盤不快感症候群として知られています。すぐに頻繁に排尿したいという症状があります。生活の質の低下やうつ病は IC/BPS に関連しています。罹患した人の多くは線維筋痛症や過敏性腸症候群にも苦しんでいます。
北米の間質性膀胱炎市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に10.8％のCAGRで成長し、2029年までに11億2,331万米ドルに達すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019-2014 にカスタマイズ可能) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
重症度（軽度から中等度、中等度から重度）、治療タイプ（薬物療法、膀胱点滴、ボツリヌス毒素A、神経刺激療法、手術）、投与経路（経口、非経口、膀胱内、局所、その他）、購入方法（市販薬、処方薬）、患者タイプ（小児および成人）、エンドユーザー（病院、診療所、在宅医療、その他）、流通チャネル（直接入札、小売販売、その他） |
|
対象国 |
米国、カナダ、メキシコ。 |
|
対象となる市場プレーヤー |
Alvogen、Janssen Pharmaceuticals、Inc.、Sandoz AG、Sun Pharmaceutical Industries Ltd.、Accord Healthcare US、Avet Pharmaceuticals Inc.、Lannett、Viatris Inc.、Pfizer、Inc.、Strides Pharma Science Limited、GSK plc、Prestige Consumer Healthcare Inc.、Amneal Pharmaceuticals LLC、Zydus Pharmaceuticals、Inc.、Apotex Inc.、Aurobindo Pharma USA、VistaPharm、Inc.、Dr. Reddy's Laboratories、Inc.、Teva Pharmaceuticals USA、Inc.、Bayer AG、Reckitt Benckiser Group PLC など。 |
市場の定義
間質性膀胱炎として知られる持続的な病気は、膀胱の圧迫感、膀胱の痛み、骨盤痛を引き起こします。軽度の不快感から重度の苦痛まで、あらゆる痛みのレベルがあります。この障害は、膀胱痛症候群と呼ばれる病気のグループに属します。医師は、X線検査、尿検査、膀胱鏡を使用した膀胱壁検査など、さまざまな検査を行って膀胱痛障害を診断します。膀胱痛障害は、頻尿や持続的な尿意切迫感など、少なくとも1つの他の排尿症状を伴い、6か月以上続く膀胱に関連していると思われる痛み、圧迫感、不快感が特徴です。これらの膀胱障害は、一般に膀胱炎と呼ばれる膀胱の炎症を引き起こします。障害の治療は、問題の原因によって異なります。重症例では、薬物療法や手術が行われる場合があります。
間質性膀胱炎市場の動向
このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらはすべて、以下のように詳細に説明されます。
ドライバー
-
間質性膀胱炎（IC）の罹患率の増加
間質性膀胱炎（IC）として知られる疾患は、膀胱不快感症候群としても知られ、慢性または長期にわたり、不快な排尿症状を引き起こします。IC の患者は、さまざまな症状を経験する可能性があります。たとえば、骨盤領域にほとんど圧迫感、痛み、または不快感を感じない人もいます。また、ひどい膀胱痛、尿意切迫感（突然の排尿の必要性）、頻尿（より頻繁に排尿したいという欲求）に悩まされる人もいます。間質性膀胱炎市場の成長率に影響を与える主な要因の 1 つは、今日、間質性膀胱炎の罹患率が高まっていることです。女性は特にこの症状に悩まされています。一般的な副作用には、アレルギー、線維筋痛、子宮内膜症などがあります。頻尿、尿意切迫感、骨盤痛は、日中と夜間の両方で発生する可能性のある間質性膀胱炎の臨床症状です。
-
医療費の増加
各国で人々の可処分所得が増加したため、医療費は世界的に上昇しています。さらに、政府機関や医療提供者は、国民のニーズを満たすために医療費の支出を増やすという取り組みを主導しています。
例えば、
-
2020年12月の世界保健機関（WHO）の報告書によると、2018年の医療費は8.3兆米ドルと増加しており、2016年の7.6兆米ドルと比較してGDP（国民1人当たり1.080米ドル）の約10％に相当します。さらに、世界の医療費は2000年から2017年の間に3.9％増加しました。
医療費の増加は、経済成長と医療部門の成長にも寄与しています。これは主に、市場におけるより優れた先進的な医療製品の開発に大きく影響するため、有益です。そのため、医療費の急増は、間質性膀胱炎市場の推進力となることが期待されています。
機会
-
医療システムの改善
Interstitial cystitis or bladder pain syndrome is a chronic pelvic pain syndrome related to the urinary bladder. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. Thus, improvement in one or more symptoms of bladder pain can be particularly effective in improving residual urine and bladder hyperextension.
As a result of rising infectious diseases worldwide, it is required to build a better healthcare system for the diagnosis of various infections in underdeveloped regions. Improving healthcare systems in underdeveloped regions can fuel market growth over the forecast period.
These awareness programs helped people understand the correct treatment at an appropriate time. This increasing awareness allows the consumers to select novel treatments as per age and it is efficacy, which enhances the sales of different types of products. Thus, improving a better healthcare system is expected to act as an opportunity for North America interstitial cystitis market growth in the forecasted period.
Restraints/Challenges
However, the barriers to interstitial cystitis treatment techniques and the high cost of the treatment process in some regions may impede the growth of interstitial cystitis treatment hampering the market growth. Additionally, high competition in medical technology industries and long lead time for the overseas qualification can be challenging factors for the growth of the market.
This interstitial cystitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer surgery market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you to make an informed market decision to achieve market growth.
Recent Development
- In July 2020, UCB and Ferring Pharmaceuticals Inc. announced they had entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA used for interstitial cystitis.
- In April 2021, Kyorin Pharmaceutical Co., Ltd., a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis “Zymso Intravesical Solution 50 %.
North America Interstitial Cystitis Market Scope
北米の間質性膀胱炎市場は、重症度、治療タイプ、投与経路、購入方法、患者タイプ、エンドユーザー、流通チャネルに分類されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
重大度
- 軽度から中等度
- 中等度から重度
重症度に基づいて、北米の間質性膀胱炎市場は軽度から中等度と中等度から重度に分類されます。
治療の種類
- 医薬品
- 膀胱注入
- ボツリヌス毒素A
- 神経刺激
- 手術
治療の種類に基づいて、北米の間質性膀胱炎市場は、薬物療法、膀胱点滴、ボツリヌス毒素A、神経刺激、手術に分類されます。
投与経路
- オーラル
- 非経口
- 膀胱内
- 話題
- その他
投与経路に基づいて、北米の間質性膀胱炎市場は、経口、非経口、膀胱内、局所、その他に分類されます。
購入方法
- 店頭
- 処方箋
購入方法に基づいて、北米の間質性膀胱炎市場は、市販薬と処方薬に分類されます。
患者タイプ
- 小児科
- 大人
患者タイプに基づいて、北米の間質性膀胱炎市場は小児と成人に分類されます。
エンドユーザー
- 病院
- クリニック
- 在宅医療
- その他
エンドユーザーに基づいて、北米の間質性膀胱炎市場は、病院、診療所、在宅医療、その他に分類されます。
流通チャネル
- 直接入札
- 小売販売
- その他
流通チャネルに基づいて、北米の間質性膀胱炎市場は、直接入札、小売販売、その他に分類されます。
間質性膀胱炎市場の地域分析/洞察
間質性膀胱炎市場が分析され、上記のように国、重症度、治療の種類、投与経路、購入方法、患者の種類、エンドユーザー、流通チャネル別に市場規模の洞察と傾向が提供されます。
米国は、市場シェアと収益の面で北米間質性膀胱炎市場を支配しており、予測期間中もその優位性を維持し続けるでしょう。これは、この地域で間質性膀胱炎治療プロセスの検証と検証の必要性が高まっているためであり、急速な研究開発が市場を後押ししています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。
競争環境と間質性膀胱炎の市場シェア分析
間質性膀胱炎市場の競争環境は、競合他社による詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の長所と短所、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。上記のデータ ポイントは、間質性膀胱炎市場に対する会社の重点にのみ関連しています。
間質性膀胱炎市場で活動している主要企業としては、Alvogen、Janssen Pharmaceuticals、Inc.、Sandoz AG、Sun Pharmaceutical Industries Ltd.、Accord Healthcare US、Avet Pharmaceuticals Inc.、Lannett、Viatris Inc.、Pfizer、Inc.、Strides Pharma Science Limited、GSK plc、Prestige Consumer Healthcare Inc.、Amneal Pharmaceuticals LLC、Zydus Pharmaceuticals、Inc.、Apotex Inc.、Aurobindo Pharma USA、VistaPharm、Inc.、Dr. Reddy's Laboratories、Inc.、Teva Pharmaceuticals USA、Inc.、Bayer AG、Reckitt Benckiser Group PLC などがあります。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、北米と地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA INTERSTITIAL CYSTITIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET
4.4 EPIDEMIOLOGY
5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: REGULATIONS
5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES
5.3 JAPAN REGULATORY GUIDANCE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)
6.1.2 RISE IN HEALTHCARE EXPENDITURE
6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS
6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY
6.1.5 RISING DISEASE MANAGEMENT PROGRAMS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS
6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS
6.2.3 DEARTH OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO
6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES
6.3.3 IMPROVING HEALTHCARE SYSTEM
6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.4.2 PATENT EXPIRY OF DRUGS
7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY
7.1 OVERVIEW
7.2 MILD TO MODERATE
7.3 MODERATE TO SEVERE
8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANALGESICS
8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
8.2.1.1.1 IBUPROFEN
8.2.1.1.2 NAPROXEN
8.2.1.1.3 OTHERS
8.2.1.2 ACETAMINOPHEN
8.2.1.3 NON-NARCOTIC PAIN MEDICATION
8.2.1.3.1 METHENAMINE
8.2.1.3.2 PHENAZOPYRIDINE
8.2.1.3.3 OTHERS
8.2.1.4 NARCOTIC PAIN MEDICATION
8.2.1.4.1 CODEINE
8.2.1.4.2 HYDROCODONE
8.2.1.4.3 OXYCODONE
8.2.1.4.4 OXYMORPHONE
8.2.1.4.5 MORPHINE
8.2.1.4.6 HYDROMORPHONE
8.2.1.4.7 METHADONE
8.2.1.4.8 OTHERS
8.2.2 ANTIHISTAMINES
8.2.2.1 LORATADINE
8.2.2.2 HYDROXYZINE
8.2.2.3 OTHERS
8.2.3 TRICYCLIC ANTIDEPRESSANTS
8.2.3.1 AMITRIPTYLINE
8.2.3.2 IMIPRAMINE
8.2.3.3 OTHERS
8.2.4 IMMUNOSUPPRESSANTS
8.2.4.1 CYCLOSPORINE
8.2.4.2 MYCOPHENOLATE
8.2.4.3 OTHERS
8.2.5 PENTOSAN POLYSULFATE SODIUM
8.2.6 OTHERS
8.2.6.1 ALPHA BLOCKERS
8.2.6.1.1 DOXAZOSIN
8.2.6.1.2 TERAZOSIN
8.2.6.1.3 TAMSULOSIN
8.2.6.1.4 OTHERS
8.2.6.2 AMPHETAMINES
8.2.6.3 LEUKOTRIENE INHIBITORS
8.2.6.3.1 MONTELUKAST
8.2.6.3.2 ZAFIRLUKAST
8.2.6.3.3 OTHERS
8.2.6.4 OTHERS
8.3 BLADDER INSTILLATIONS
8.3.1 DIMETHYL SULFOXIDE
8.3.2 HEPARIN
8.3.3 OTHERS
8.4 BOTULINUM TOXIN A
8.5 SURGERY
8.5.1 FULGURATION
8.5.2 RESECTION
8.5.3 BLADDER AUGMENTATION
8.6 NERVE STIMULATIONS
9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.2.1 TABLETS
9.2.1.1 EXTENDED RELEASE
9.2.1.2 IMMEDIATE RELEASE
9.2.2 CAPSULES
9.2.3 OTHERS
9.3 PARENTERAL
9.4 INTRAVESICAL
9.5 TOPICAL
9.6 OTHERS
10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE
10.1 OVERVIEW
10.2 OVER THE COUNTER
10.3 PRESCRIPTION
11 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULTS
11.3 PEDIATRIC
12 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 PHARMACY STORES
13.3.2 ONLINE RETAIL CHANNEL
13.3.3 OTHERS
13.4 OTHERS
14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENTS
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 HIKMA PHARMACEUTICALS PLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR. REDDY'S LABORATORIES LTD
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 BAYER AG
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 AMNEAL PHARMACEUTICAL LLC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 APOTEX
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 AUROBINDO PHARMA USA
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 AVET PHARMACEUTICALS INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ALVOGEN
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 10.3RECENT DEVELOPMENT
17.11 ACCORD-UK LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 11.3RECENT DEVELOPMENT
17.12 GLAXOSMITHKLINE PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 12.2REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 JOHNSON & JOHNSON SERVICES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 LANNETT
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PRESTIGE CONSUMER HEALTHCARE
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 PFIZER INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 RECKITT BENCKISER GROUP PLC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 STRIDES PHARMA SCIENCE LIMITED.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 VISTA PHARM INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 ZYDUS PHARMACEUTICALS INC.,
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 2 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA MILD TO MODERATE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA MODERATE TO SEVERE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA BOTULINUM TOXIN A IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA NERVE STIMULATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA PARENTERAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA INTRAVESICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA TOPICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA OVER THE COUNTER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA PRESCRIPTION IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA ADULTS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA PEDIATRIC IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA HOSPITALS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA CLINICS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA HOME HEALTHCARE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA DIRECT TENDER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 NORTH AMERICA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 NORTH AMERICA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 NORTH AMERICA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 65 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 66 NORTH AMERICA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 68 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 U.S. INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 73 U.S. INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.S. MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.S. ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 U.S. NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.S. NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.S. ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 U.S. IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.S. TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 U.S. OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 U.S. ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 U.S. LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.S. BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 U.S. SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 U.S. INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 88 U.S. ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 U.S. TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 U.S. INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 91 U.S. INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.S. INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.S. INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 U.S. RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 CANADA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 96 CANADA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 97 CANADA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 CANADA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 CANADA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 CANADA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 CANADA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 CANADA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 CANADA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 CANADA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 CANADA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 CANADA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 CANADA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 CANADA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 CANADA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 111 CANADA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 112 CANADA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 113 CANADA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 114 CANADA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 115 CANADA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 CANADA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 CANADA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 118 MEXICO INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 119 MEXICO INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 MEXICO MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 MEXICO ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 MEXICO NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 MEXICO NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 MEXICO ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 MEXICO IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 MEXICO TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 MEXICO OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 MEXICO ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 MEXICO LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 MEXICO BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 MEXICO SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 MEXICO INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 134 MEXICO ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 135 MEXICO TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 136 MEXICO INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 137 MEXICO INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 MEXICO INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 MEXICO INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 140 MEXICO RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET
FIGURE 14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021
FIGURE 15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021
FIGURE 19 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 23 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021
FIGURE 27 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021
FIGURE 31 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021
FIGURE 35 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 40 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 41 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021)
FIGURE 43 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021)
FIGURE 44 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029)
FIGURE 47 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
